We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+1.35%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$790M
AUM Growth
-$75.1M
Cap. Flow
-$71M
Cap. Flow %
-8.98%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$59.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$6.48M
3
GBIO
Generation Bio
GBIO
+$4.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.51B
$381M 48.26%
4,578,008
-81,866
-2% -$6.48M
DYN icon
2
Dyne Therapeutics
DYN
$4.85B
$166M 20.95%
9,130,465
– –
SION
3
Sionna Therapeutics
SION
$296M
$120M 15.2%
2,995,602
– –
IRON icon
4
Disc Medicine
IRON
$3.09B
$96.8M 12.25%
1,513,875
– –
QTTB icon
5
Q32 Bio
QTTB
$458M
$13.4M 1.7%
2,092,106
– –
KRRO icon
6
Korro Bio
KRRO
$197M
$12.9M 1.63%
1,137,149
– –
DAWN
7
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-6,412,560
Closed -$59.8M
GBIO
8
DELISTED
Generation Bio
GBIO
– –
-827,946
Closed -$4.7M

Similar funds

OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
AGDI
Absolute Gestao de Investimentos Sao Paulo, Brazil $877M AUM 57.36% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return
FCM
FJ Capital Management Mclean, Virginia $888M AUM 18.97% 1-Year Est. Return
SA
SoftVest Advisors Abilene, Texas $872M AUM 28.76% 1-Year Est. Return
F1I
Fund 1 Investments Rincon, Puerto Rico $872M AUM 50.95% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return
WCM
Wallace Capital Management Dallas, Texas $871M AUM 13.69% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Atlas Venture Life Science Advisors held 8 positions worth $790M, down 8.7% from $865M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Life Science Advisors withdrew a net $71M in Q1 2026, closing 2 positions and reducing 1 holding. Its most notable exit was Day One Biopharmaceuticals, an estimated $59.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q1 2026 reduction was Kymera Therapeutics, cutting an estimated $6.48M.
  • Atlas Venture Life Science Advisors fully exited Day One Biopharmaceuticals in Q1 2026, selling an estimated $59.8M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $790M portfolio in Q1 2026.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 2 in Q1 2026.
  • Atlas Venture Life Science Advisors's portfolio value fell 8.7% quarter-over-quarter to $790M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2026, filed 14 May 2026.